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Abstract
Background: ATP-binding cassette (ABC) transporters are transmembrane proteins responsible for the efflux of a
wide variety of substrates, including steroid metabolites, through the cellular membranes. For better
characterization of the role of ABC transporters in prostate cancer (PCa) development, the profile of ABC transporter
gene expression was analyzed in PCa and noncancerous prostate tissues (NPT).
Methods: TaqMan Low Density Array (TLDA) human ABC transporter plates were used for the gene expression
profiling in 10 PCa and 6 NPT specimens. ABCB1 transcript level was evaluated in a larger set of PCa cases (N = 78)
and NPT (N = 15) by real-time PCR, the same PCa cases were assessed for the gene promoter hypermethylation by
methylation-specific PCR.
Results: Expression of eight ABC transporter genes (ABCA8, ABCB1, ABCC6, ABCC9, ABCC10, ABCD2, ABCG2, and
ABCG4) was significantly down-regulated in PCa as compared to NPT, and only two genes (ABCC4 and ABCG1) were
up-regulated. Down-regulation of ABC transporter genes was prevalent in the TMPRSS2-ERG-negative cases.
A detailed analysis of ABCB1 expression confirmed TLDA results: a reduced level of the transcript was identified in
PCa in comparison to NPT (p = 0.048). Moreover, the TMPRSS2-ERG-negative PCa cases showed significantly lower
expression of ABCB1 in comparison to NPT (p = 0.003) or the fusion-positive tumors (p = 0.002). Promoter
methylation of ABCB1 predominantly occurred in PCa and was rarely detected in NPT (p < 0.001).
Conclusions: The study suggests frequent down-regulation of the ABC transporter genes in PCa, especially in the
TMPRSS2-ERG-negative tumors.
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Background
ATP-binding cassette (ABC) transporters are transmem-
brane proteins responsible for the transfer of a wide var-
iety of substrates through the extra- and intra-cellular
membranes [1]. Cellular metabolites, lipids, sterols,
drugs, and other xenobiotics are known as the substrates
for ABC transporters. The human genome contains 51
ABC transporter genes (and pseudogenes) arranged in
seven subfamilies and named from A to G [2]. In cancer
cells, the over-expression of several ABC transporters is
related to an increased efflux of chemotherapeutic drugs
and the development of multidrug resistance [3]. The
strongest connections with multidrug-resistant cancer
have been identified for ABCB1 (also known as MDR1
or P-glycoprotein), ABCC1 (also known as MRP1), and
ABCG2 (also known as BCRP or MXR) transporters.
However, in prostate cancer (PCa), the highly prevalent
male malignancy, the studies of ABC transporters are
quite limited. Androgens and other steroid hormones
are important for the normal development and mainten-
ance of the prostate gland, but they also participate in
prostate tumorigenesis. Androgen deprivation therapy
through surgical or medical castration is an effective
treatment strategy of PCa, but during the disease pro-
gression the sensitivity to residual androgens increases
resulting in aggressive forms of castration-resistant PCa.
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steroid efflux capacities of ABC transporters and the
progression of PCa [4].
ABCB1 is the most studied ABC transporter in PCa.
Differently from other tumors, down-regulation rather
than over-expression of the ABCB1 gene has been iden-
tified in PCa [5–7]. Aberrant DNA methylation and his-
tone modifications are the main mechanisms responsible
for the inactivation of this locus in PCa [7–9]. ABCB1
expression has been related to the efflux of androgens
from PCa cell lines [10] suggesting that reduced levels of
ABCB1 might be responsible for intratumoral androgen
accumulation and sustained signaling from androgen re-
ceptors (ARs) [4]. ABCA1, another important trans-
porter of the ABC family, was recently shown to be
related to the development of aggressive PCa through
the impaired efflux of cholesterol, an alternative source
for androgen synthesis [11]. Several other ABC trans-
porters were shown as the potent regulators of intracel-
lular levels of steroid metabolites, including androgens
and antiandrogens [12–14]. Additionally, expression of
several ABC transporters was shown to be regulated by
androgens or ARs [15, 16]. These data suggest signifi-
cant involvement of ABC transporters in the pathogen-
esis of PCa and encourage more detailed analysis of
gene expression of the ABC family in relation to clinical
characteristics of PCa.
Gene expression profile of human ABC transporters
was explored in cancerous and noncancerous prostate
tissue by means of TaqMan Low Density Arrays (TLDA).
Gene expression and DNA methylation of the ABCB1
gene were analyzed in a larger set of cases, and the data
were correlated with clinical characteristics of PCa. As-
sessment of the TMPRSS2-ERG transcript status enabled
identification of novel associations between this fusion
transcript and the expression of ABC transporter genes.
Methods
Sample collection and clinical data
Prostate tissue samples were obtained from 104 PSA-
screened and biopsy-proven PCa patients treated with a
radical prostatectomy (RP) at the Vilnius University
Urology Centre from 2008 to 2014. The research was a
part of large-scale PCa biomarker study conducted ac-
cording to standardised protocols of sample collection
and processing reported previously [17]. Cancerous
(≥70 % of tumor cells) and noncancerous (0 %) prosta-
tectomy tissues were sampled by expert pathologist as
previously reported [17] and prepared for molecular
analysis. The results of clinical, postoperative patho-
logical and molecular examinations are presented in
Table 1. None of these patients had received preopera-
tive radiotherapy, chemotherapy, or hormonal treatment.
Approval from the Lithuanian Bioethics Committee was
obtained before initiating the study and all patients gave
informed consent for participation.
Prostate tumors of a Gleason score 6–8 and of an
intermediate stage (pT2-pT3) were included in our study
(Table 1). Ten PCa and 6 noncancerous prostate tissues
(NPT) were screened on human ABC transporter TLDA
cards. The ABCB1 gene expression analysis was per-
formed on 78 PCa tissues and 15 NPT specimens from
PCa patients. The same (N = 78) PCa specimens and a
set of NPT samples (N = 9) were analyzed for the ABCB1
gene promoter DNA methylation. Ten additional NPT
samples were included in this analysis, resulting in a
control group of 19 NPT specimens. Follow-up data
were available for 93.59 % (73/78) of patients with a
mean follow-up time of 3 years. Biochemical recurrence
(BCR) was defined as a detection of serum PSA level of
>0.20 ng/mL by two subsequent measurements after RP.
The status of the fusion transcript TMPRSS2-ERG was
identified as reported previously [17].
Gene expression analysis with TLDA
Total RNA from snap-frozen sections was isolated with
mirVana Kit (Ambion, Life Technologies, Thermo Fisher
Scientific Foster City, CA, USA) according to the manu-
facturer’s recommendations. The quantity of the RNA
samples was measured spectrophotometrically using the
NanoDrop 2000 (Thermo Fisher Scientific, Wilmington,
NC, USA). Integrity (RIN) of the RNA samples was
checked with the 2100 Bioanalyzer system (Agilent
Technologies, Santa Clara, CA, USA).
Reverse transcription (RT) was done using 500 ng
of total RNA and High Capacity cDNA Reverse Tran-
scription Kit with RNase Inhibitor according to the
manufacturer’s instructions (Applied Biosystems, Life
Technologies, Thermo Fisher Scientific, Foster city,
CA, USA).
Gene expression of human ABC transporters was pro-
filed using TLDA cards with the human ABC trans-
porter panel (Applied Biosystems), containing 50 human
ABC transporter genes and 14 proposed reference genes.
Twenty μL of cDNA were used as a template for the
measurement of mRNA in quantitative PCR (qPCR).
RT-qPCR was performed using TaqMan Universal Mas-
ter Mix II, no UNG from Applied Biosystems on the
ViiA 7 Real-Time PCR System as recommended by the
manufacturer (Applied Biosystems). Thermal cycling
conditions were as follows: 95 °C for 10 min, then 95 °C
for 15 s and 60 °C for 1 min for 40 cycles.
Raw Cq-values with automatically selected thresholds
were calculated using the ViiA 7 version 1.1 software
(Applied Biosystems). Expression level of each gene for
all samples was analyzed in triplicate and required at
least two valid wells. Only genes having ≥70 % of valid
data of all samples were involved in further analyses.
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According to the NormFinder and GeNorm algorithms
the combination of POLR2A, PGK1, PPIA, ACTB, B2M,
and HMBS was shown as the most suitable set of refer-
ence genes and was used for further TLDA data analysis.
Target gene RT-qPCR
Total RNA from snap-frozen sections was isolated using
the phenol-chloroform method. Quantity of the RNA
samples was measured spectrophotometrically using the
NanoDrop 2000 (Thermo Fisher Scientific). For RT-
qPCR, 1 μg of total RNA was converted to cDNA using
Maxima First Strand cDNA Synthesis Kit for RT-qPCR
(Thermo Fisher Scientific) in a final volume of 20 μL. RT
products were amplified on Mastercycler-pro thermocy-
cler (Eppendorf, Hamburg, Germany) under the following
conditions: 25 °C for 10 min, followed by 50 °C for
15 min, and the termination of reaction by heating at
85 °C for 5 min. A negative control without reverse
transcriptase was included for each sample.
ABCB1 expression was analyzed by RT-qPCR with SYBR
Green labeling using the following primers: F-5´-CCCATC
ATTGCAATAGCAGG-3´ and R-5´-GTTCAAACTTCTG
CTCCTGA-3´. GAPDH was used as a reference gene and
the product was amplified with the primers: F-5´-GA
AGGTCGGAGTCAACGGATTT-3´and R-5´-ATGGG
TGGAATCATATTGGAAC-3´ (all from Metabion
International AG, Martinsried, Germany).
RT-qPCR mix was prepared using Maxima SYBR Green
qPCR Master Mix (2X) (Thermo Fisher Scientific),
0.3 μM forward and reverse primers, and 2 μL cDNA in a
total volume of 25 μL. Well-to-well variation was normal-
ized by adding 10 nM ROX. QPCR was performed on the
Viia7 Real-Time PCR System (Applied Biosystems) under
the following conditions: enzyme activation at 50 °C for
2 min followed by 95 °C for 10 min, then amplification at
95 °C for 15 s and 60 °C for 1 min for 40 cycles in total,
and the melting step at default parameters. Cq values were
calculated with Viia7 software version 1.1 (Applied Biosys-
tems). All gene assays were measured in duplicate and
Table 1 Characteristics of study group. ABCB1 analysis group was involved in the ABCB1 gene expression and methylation
analysis, while TLDA analysis group was profiled for the ABC transporter genes expression. NPT – noncancerous prostate
tissue; PCa – prostate cancer; BCR – biochemical recurrence; PSA – prostate-specific antigen
Variable ABCB1 analysis group TLDA analysis group
N = 93 N = 16
NPT PCa NPT PCa
N = 15 + 10a N = 78 N = 6 N = 10















Mean PSA level at diagnosis, ng/ml ± SEM 10.57 ± 1.25 11.07 ± 3.03
Methylation status of ABCB1 promoter
Methylated 4 56 5
Unmethylated 15 22 5
Unknown 6 6
Mean expression of ABCB1, ΔCq ± SEM 7.50 ± 0.24 8.14 ± 0.13 5.01 ± 0.18 5.61 ± 0.17
aTen additional samples were included in ABCB1 methylation analysis
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required at least two valid wells. A negative control with-
out cDNA was included for each primer pair in every RT-
qPCR run.
DNA methylation analysis
Up to 20 mg of prostate tissue were digested with
proteinase-K and DNA was extracted using standard
phenol-chloroform protocol followed by ethanol precipi-
tation. Modification with sodium bisulfite was performed
using EZ DNA Methylation Kit (Zymo Research, Irvine,
CA, USA) according to the manufacturer’s protocol.
Bisulfite-modified DNA was used as a template for
methylation-specific PCR (MSP) with ABCB1 primers
[18] specific for either methylated or unmethylated DNA.
The MSP reaction mix (25 μL) contained 1x AmpliTaq
Gold Buffer, 2.5 mM MgCl2, 1.6 mM dNTP mix, 1.25 U
AmpliTaq Gold 360 DNA Polymerase (Applied Biosys-
tems), 0.5 μM of each primer, and 1 μL of bisulfite-
modified DNA. Amplification conditions were as follows:
95 °C for 10 min, then 37 cycles at 95 °C for 45 s, 60 °C
for 45 s, and 72 °C for 45 s, and final extension at 72 °C
for 10 min. The MSP products were run on 3 % agarose
gel with ethidium bromide staining. Bisulfite-modified
leukocyte DNA from healthy donors served as a negative
control for methylated DNA and SssI methylase-treated
(Thermo Fisher Scientific) bisulfite-modified leukocyte
DNA served as a positive control. Non-template controls
were included in each PCR run.
Statistical analysis
Computation of statistical tests was performed using
GraphPad Prism version 5.00 for Windows (GraphPad
Software, San Diego California USA) and GenEx version
6.0.1 software (MultiD Analyses AB, Göteborg, Sweden).
Survival analysis of the TLDA cohort was carried out
with MedCalc Statistical Software version 14.12.0 (Med-
Calc Software, Ostend, Belgium). A t-test indicated rela-
tive gene expression differences between two groups.
For methylation data, a Mann–Whitney U-test (for con-
tinuous variables) and a two-tailed Fisher’s exact test
(for categorical variables) were applied to identify statis-
tically significant differences between groups. Spearman’s
correlation coefficient was calculated to identify signifi-
cant associations. P-values of less than 0.05 were consid-
ered significant.
Results
Gene expression profile of ABC transporters in PCa
In order to explore the expression levels of the ABC
genes, 10 PCa and 6 NPT samples were profiled on
human ABC transporter TLDAs containing probes for
50 ABC genes in total. Expression of 45 genes was con-
sistently identified in prostate tissue, with the highest
levels (mean Cq < 24) characteristic to ABCA11, ABCC4,
ABCD3, ABCE1, and ABCF3. In contrast, the ABCB5,
ABCC12, ABCC13, ABCG5, and ABCG8 genes showed
low or undetectable expression (mean Cq > 35) in pros-
tate tissue and were eliminated from further analysis.
Comparison of PCa to NPT revealed a specific ABC gene
expression signature of PCa characterized by marked
down-regulation of several ABC transporter genes (Fig. 1a).
Eight ABC transporter genes were significantly down-regu-
lated in cancerous prostate tissues (Fig. 1b and c), includ-
ing ABCA8 (FC 2.03; p = 0.029), ABCB1 (FC 1.52; p =
0.035), ABCC6 (FC 5.67; p = 0.005), ABCC9 (FC 2.77;
p < 0.001), ABCC10 (FC 1.24; p = 0.030), ABCD2 (FC
2.44; p < 0.001), ABCG2 (FC 2.22; p = 0.003), and
ABCG4 (FC 2.14; p < 0.001; Fig. 1c). Only two out of
45 analyzed ABC transporter genes, namely ABCC4
(FC 2.49; p = 0.007) and ABCG1 (FC 1.48; p = 0.029),
were up-regulated in PCa in comparison to NPT
(Fig. 1b and c, Additional file 1).
Remarkably, a quite different profile of ABC gene ex-
pression was observed in PCa stratified according to the
TMPRSS2-ERG transcript status. ABCA8 and ABCC9,
the genes that were significantly down-regulated in PCa
in comparison to NPT, showed high expression in the
TMPRSS2-ERG-positive cases, but were suppressed in
the fusion-negative cases. The total list of ABC trans-
porters that were down-regulated in the TMPRSS2-ERG-
negative cases included ABCA8 (FC 2.56; p = 0.012),
ABCA13 (FC 5.35; p = 0.039), ABCC9 (FC 1.74; p = 0.037),
and ABCF1 (FC 1.57; p = 0.038; Fig. 2, Additional file 1).
PCa cases that experienced BCR (N = 5) showed sig-
nificant reduction of the ABCA11 gene expression (FC
2.03; p = 0.031; Additional file 1). The expression level
of ABCA11 was negatively correlated with tumor size
(R −0.83; p = 0.003) and extra-prostatic tumor stage
(FC 2.05; p = 0.028). Univariate survival analysis re-
vealed borderline significance of ABCA11 expression
(p = 0.072) in predicting BCR.
In addition to ABCA11, the extra-prostatic tumor stage
(pT3 vs pT2) was associated with the down-regulation of
other ABC transporter genes from subfamily A (Fig. 2,
Additional file 1): ABCA5 (FC 1.73; p = 0.022), ABCA6
(FC 2.00; p = 0.046), and ABCA10 (FC 3.29; p = 0.006). In
contrast, the higher Gleason score (Gleason 7 vs 6) was
related to over-expression of several genes: ABCA2 (FC
1.47; p = 0.041), ABCA4 (FC 2.41; p = 0.038), and ABCF3
(FC 1.44; p = 0.041). This might be explained by the pre-
dominance of the TMPRSS2-ERG-positive cases among
tumors with Gleason score 7.
ABCB1 expression and DNA methylation in PCa
For the verification of TLDA results, expression of the
ABCB1 gene was evaluated in a larger group of PCa
cases (N = 78) and NPT (N = 15) specimens. As in the
TLDA analysis, the ABCB1 expression was significantly
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Fig. 1 Profile of ABC transporter gene expression in prostate cancer (PCa) and noncancerous prostate tissue (NPT). Heat maps represent
expression profile of all analyzed (a) and significantly (p < 0.05) deregulated (b) ABC genes. Box plots (c) show expression levels of significantly
deregulated ABC genes. The box extends from the 25th to 75th percentiles. The line in the middle of the box is plotted at the median. The
whiskers indicate the smallest and largest values
Fig. 2 Significant changes (p < 0.05) of ABC transporter gene expression in PCa according to selected variables. F+/− − TMPRRS2-ERG fusion
status; BCR – biochemical recurrence; G7/6 – Gleason score 7/6; pT3/2 – pathological tumor stage 3/2. The box extends from the 25th to
the 75th percentiles. The line in the middle of the box is plotted at the median. The whiskers indicate the smallest and largest values
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lower in PCa than in NPT tissues (FC 1.56; p = 0.048;
Fig. 3a). Moreover, the TMPRSS2-ERG-negative PCa cases
showed significantly lower ABCB1 expression in compari-
son to the fusion-positive tumors (FC 1.77; p = 0.002) or
NPT (FC 2.90; p = 0.003). A negative association (R −0.29;
p = 0.012) was detected between ABCB1 expression and
the preoperative PSA level. No other significant correla-
tions with clinical variables (pT or Gleason score) were
identified, and similar levels of ABCB1 were observed in
BCR and no-BCR cases (Fig. 3a).
The MSP analysis (Fig. 3b) was applied for the detec-
tion of aberrant DNA methylation in the promoter re-
gion of the ABCB1 gene in the same set of PCa cases.
More than 70 % of PCa tissues (56/78; 71.79 %) showed
aberrant ABCB1 promoter methylation, while this change
rarely occurred in NPT specimens (4/19; p < 0.001). Com-
parison to gene expression data revealed statistically
significantly lower levels the ABCB1 transcript in the PCa
tissues with the promoter hypermethylation as compared
to the cases without hypermethylation (FC 1.66; p = 0.011;
Fig. 3a). Similarly to the gene expression, no statistically
significant correlations between the ABCB1 methylation
status and clinical variables were identified.
CpG islands of the ABC transporter genes
To test the possible involvement of DNA methylation in
transcriptional regulation of other ABC genes, CpG
islands (CGI) of the significantly deregulated ABC pro-
moters were characterized based on data provided by
the NCBI Epigenomics browser. For genes with no CGIs
present, the DBCAT online tool [19] was used to predict
potential CGIs, applying the following parameters: ob-
served/expected CpG ratio 0.6, minimal CGI length
300 bp, and GC content ≥50 %. Promoter regions were
obtained from the Swiss Regulon Portal [20] or from the
Eukaryotic Promoter Database [21]. Typical CGIs were
identified in 5’ regions in 12 out of 19 (74 %) significantly
deregulated ABC genes, and 2 additional CGIs were
predicted using CGI detection tool (Table 2). Mean
length of the identified CGIs was more than 1 kb, the
GC content exceeded 70 %, and most of the CGIs were
located in the promoter regions of the ABC genes. Only
two out of these 14 CGIs of the ABC genes (ABCB1
and ABCG2) have been studied for DNA methylation
changes in PCa [7–9, 22–24], while others deserve fur-
ther investigations.
Discussion
Current evidence suggests a role for membrane trans-
porters in control of intratumoral androgen level im-
portant for PCa development and progression [10–14].
In the present study, for the better characterization of
the role of ABC transporters in prostate tumorigenesis,
expression levels of all human ABC transporter genes
were evaluated for the first time in cancerous and non-
cancerous prostate tissue. This study identified a specific
profile of ABC gene expression in PCa characterized by
the down-regulation of several ABC genes. Deregulated
expression of a set of ABC genes was particularly evi-
dent in the TMPRSS2-ERG-negative prostate tumors.
Expression of 45 out of 50 ABC transporter genes
loaded on the array was identified in prostate tissue,
while five genes showed low or undetectable levels of ex-
pression. Transcription levels of eight ABC transporter
genes, including ABCA8, ABCB1, ABCC6, ABCC9,
ABCC10, ABCD2, ABCG2, and ABCG4, were signifi-
cantly down-regulated in PCa, and only two genes,
ABCC4 and ABCG1, were up-regulated. In a larger set
of PCa cases, the expression of ABCB1 was also signifi-
cantly reduced in PCa relative to NPT, and this suppres-
sion was associated with increased preoperative PSA
level. Our data are in agreement with other studies of
ABC transporters in PCa. Several studies reported the
down-regulation of the ABCB1 gene [5–7] and reduced
Fig. 3 Expression levels (a) and methylation frequency (b) of ABCB1 in prostate tissues. PCa – prostate cancer; NPT – noncancerous prostate
tissue; BCR – biochemical recurrence; F+/− – TMPRRS2-ERG fusion status. The box of figure A extends from the 25th to the 75th percentiles.
The line in the middle of the box is plotted at the median. The whiskers indicate the smallest and largest values
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levels of protein expression [9] in PCa in comparison to
NPT. Similarly, loss of the ABCA1 protein expression
was detected in PCa, especially in the higher grade tu-
mors [11]. The ABCA5 protein was detectable in basal
cells of normal prostate glands and premalignant lesions,
but was faintly expressed in prostate cancer glands [25].
Down-regulation of the ABCC4 or ABCG2 transporters
was recently reported in PCa [16, 23]. Expression of
ABCC4 was shown to be reduced after androgen abla-
tion, and castration-resistant PCa cases had lower levels
of this transporter [15, 16]. Expression or functional ac-
tivities of the remaining members of this large gene fam-
ily are mainly unexplored in PCa.
DNA hypermethylation is a powerful mechanism of
gene inactivation. In PCa, aberrant DNA methylation of
the ABCB1 promoter was reported in several studies,
and correlations with reduced gene or protein expres-
sion were identified [7–9, 26, 27]. In agreement with
these previous studies, our data showed frequent (72 %)
hypermethylation of the ABCB1 promoter in PCa, and
significant association between the aberrant methylation
and reduced expression of the transcript. Similarly, the
loss of expression of ABCA1, another transporter of the
ABC family, was recently [11] related to the aberrant
methylation of the promoter region in PCa. Besides,
comparison of the global methylation pattern of genes in
PCa cell lines and normal prostate cell lines [7] revealed
predominant hypermethylation of different membrane
transporter genes in PCa cell lines. Among them, two
genes of the ABC family, ABCB1 and ABCC7, showed
increased methylation in PCa cell lines. Similarly, hyper-
methylation of the ABCC6 gene was identified in urine
of bladder cancer patients [28]. This suggests that fre-
quent down-regulation of ABC transporter genes in
PCa, observed in our study and in other publications
[5–7, 11, 16, 23] might be caused by the gain of DNA
methylation in ABC gene loci. In support of this con-
cept, strong CpG islands were identified in loci encoding
14 out of 19 ABC genes that were deregulated in PCa
tissues in our study. This observation encourages further
investigation of epigenetic aberrations of ABC trans-
porter genes in PCa as a possible mechanism of prostate
tumorigenesis and PCa progression.
Although the TMPRSS2-ERG fusion is the most preva-
lent genetic rearrangement found in approximately 50 %
of PCa [29], the clinical implications of this gene fusion
are still unclear. The fusion transcript is usually com-
posed of the androgen-sensitive TMPRSS2 promoter and
the ERG sequence. This genetic rearrangement results in
the androgen-regulated oncogenic transcription factor.
Table 2 Characterization of CpG islands (CGIs) of significantly deregulated ABC transporter genes. CGI locations are provided relative
to transcription start site (TSS). Gene expression changes were identified in comparisons: Gleason score 7 versus 6 (G7/6); tumor
stage 3 versus 2 (pT3/2); prostate cancer versus noncancerous prostate tissue (PCa/NPT); TMPRSS2-ERG fusion transcript negative
versus positive cases (F−/+)
Gene name Gene expression Group comparison Gene location CGI presence GC content, % CGI length, bp CGI location according to TSS
ABCA2 Up G7/6 9q34 Yes 78 1196 +134/+1329
ABCA4 Up G7/6 1p22 No – – –
ABCA5 Down pT3/2 17q24.3 Yes 67 1319 −669/+650
ABCA6 Down pT3/2 17q24.3 No − − −
ABCA8 Down PCa/NPT; F−/+ 17q24 No − − −
ABCA10 Down pT3/2 17q24 No − − −
ABCA11 Down BCR+/−; pT3/2 4p16.3 Yes 63 724 −10/+714
ABCA13 Down pT3/2; F−/+ 7p12.3 Yesa 62 618 +283291/+283908
ABCB1 Down PCa/NPT; F−/+; pT3/2 7q21.12 Yes 57 1048 +112174/+113221
ABCC4 Up PCa/NPT 13q32 Yes 68 1355 −849/+506
ABCC6 Down PCa/NPT 16p13.1 Yesa 58 1397 −1022/+375
ABCC9 Down PCa/NPT; F−/+ 12p12.1 Yes 56 1019 −733/+286
ABCC10 Down PCa/NPT 6p21.1 Yes 59 964 −454/+510
ABCD2 Down PCa/NPT 12q12 No − − −
ABCF1 Down F−/+ 6p21.33 Yes 58 1222 −655/+567
ABCF3 Up G7/6 3q27.1 Yes 62 737 −269/+468
ABCG1 Up PCa/NPT 21q22.3 Yes 67 1709 −437/+1272
ABCG2 Down PCa/NPT 4q22 Yes 65 1053 −589/+464
ABCG4 Down PCa/NPT 11q23.3 Yes 73 888 −262/+626
aPredicted CGI
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In our study, despite the predominant down-regulation
of ABC transporters in PCa specimens, the TMPRSS2-
ERG fusion-positive tumors showed quite high levels of
ABCB1 and several other ABC genes in comparison to
the fusion-negative cases. cMYC, which is a direct tran-
scriptional regulator of a large set of ABC transporters,
is usually over-expressed in the fusion-positive PCa [30]
and might be responsible for this TMPRSS2-ERG fusion-
related ABC gene expression profile. More importantly,
our study revealed marked down-regulation of four ABC
transporter genes (ABCA8, ABCA13, ABCC9, and
ABCF1) in the subgroup of PCa cases that were negative
for the TMPRSS2-ERG transcript. In addition, the ex-
pression of ABCB1 was also significantly reduced in the
TMPRSS2-ERG-negative cases in our validation study.
The altered expression of ABC transporters has been
shown to reduce the efflux of androgens and their pre-
cursors [4], while intracellular accumulation of andro-
gens is responsible for sustained AR signaling. This ABC
transporters deficiency-related AR activation might serve
as an important pathway of tumorigenesis in TMPRSS2-
ERG-negative cases. Moreover, these changes in ABC
gene expression might favor development of a progres-
sive, anti-androgen therapy-resistant phenotype of PCa.
However, the exact mechanism and consequences of the
down-regulation of ABC transporter genes in PCa need
to be clarified in functional studies.
PCa is a highly variable disease with multiple genetic
and epigenetic alterations affecting a wide range of bio-
logical pathways. During recent years multiple molecu-
lar markers of PCa have been explored, however, the
implication of ABC transporters in prostate cancero-
genesis is still poorly understood. Besides extensively
documented hypermethylation of the ABCB1 promoter,
our study demonstrates that down-regulation of other
ABC transporter genes occurs in PCa. Deregulated ex-
pression of several ABC genes shows significant associ-
ations with advanced tumor stage, grade, other clinical
variables, and TMPRSS2-ERG status. Moreover, our
data indicate that a set of these significantly deregulated
ABC genes possess strong CGIs in their promoters and
might be controlled by DNA methylation and other
epigenetic phenomena. Significantly deregulated ABC
genes identified by our TLDA-based screening warrant
further investigation for their diagnostic and prognostic
potential in PCa, whereas epigenetic therapy might be
considered for treatment of androgen deprivation
therapy-resistant tumors.
Conclusions
In prostate tumors, expression of several ABC trans-
porter genes is down-regulated and shows significant
associations with clinical variables and the absence of
the TMPRSS2-ERG fusion transcript. ABCB1 analysis
and characterization of CpG islands of the ABC loci suggest
aberrant DNA methylation as a plausible mechanism in-
activating expression of the ABC transporter genes in PCa.
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